Hematopoietic Stem Cell Transplant Survivors Study (HTSS Study)

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators hope to find the proof of principle concept from this pilot study so that the investigators can design a clinical trial based on the results of the explanatory hypothesis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Dasatinib; Quercetin

Criteria

Inclusion Criteria

• Allogeneic HSCT patients surviving ≥ 1 year post-HSCT

• Diagnosis of both malignant and non-malignant conditions as HSCT indications

• HSCT survivors receiving any type of conditioning chemo/radiotherapy for HSCT

• Ability to provide written and verbal informed consent

• Age ≥ 18 years

• Adequate blood counts i.e. platelets>50,000 per microliter; HB>9/dL, and ANC> 1000 per microliter

Exclusion Criteria

• HSCT survivor with human immunodeficiency virus (HIV) infection

• HSCT survivor with active hepatitis B or C HSCT survivor on any TKI for either Philadelphia chromosome positive cancers or for GVHD treatments or for any other indication (e.g., imatinib for GIST, sorafenib for FLT3+ AML etc)

• HSCT survivor with any post-transplant maintenance chemotherapy

• Post-transplant relapse of cancer

• Active progressive CHRONIC chronic or overlap GVHD (per the NIH chronic GVHD criteria)

• Presence of uncontrolled psychiatric disorder

• Patient unable to give informed consent

• Extremely poor overall prognosis (<6 months as deemed by the primary transplant physician)

• HSCT survivors with confirmed drug addiction

• HSCT survivors with active coronary artery disease (CAD) [including angina] or active congestive heart failure (CHF)

• International HSCT survivors in whom loss to follow-up would be a concern as deemed by primary transplant physician

• Known hypersensitivity or allergy to dasatinib, or quercetin

• Presence of uncontrolled lupus

• Presence of uncontrolled pleural/pericardial effusions or ascites

• Presence of active new cancer (solid or hematologic) except non-melanoma skin cancers

• Presence of progeroid syndromes in family

• Invasive fungal or viral infection not responding to appropriate antifungal or antiviral therapies.

• Creatinine clearance < 60 mL/min/1.73 m2 based on the Cockcroft-Gault

• Inability to tolerate oral medications

• Total bilirubin>2x upper limit normal (unless deemed to be due to Gilbert's syndrome); AST/ALT>2.5x ULN

• Active progressive ACUTE graft-versus-host disease

• Active progressive OVERLAP graft-versus-host disease

• Patients taking medications that are sensitive substrates or substrates with a narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6 or strong inhibitors or inducers of CYP3A4(e.g. cyclosporine, tacrolimus or sirolimus). If antifungals are absolutely necessary from infectious disease perspective, then they will be allowed only if the levels are therapeutic. Levels will be checked at baseline and also at day +4 post intervention.

• Patients taking H2-antagonists or proton pump inhibitors.

• Patients on therapeutic doses of anticoagulants (e.g. warfarin, heparin, low molecular weight heparin, factor Xa inhibitors etc).

• On antiplatelet agents (e.g. full dose aspirin, clopidogrel etc.). Baby aspirin if absolutely necessary from cardiac perspective will be allowed.

• On any quinolone antibiotic therapy for treatment or for prevention of infections.

• QTc>450 msec. Common drugs that are well known in prolonging QTc include azithromycin, citalopram, escitalopram, fluconazole, and pentamidine. Baselines EKG will be obtained in each patient and if QTc >450 msec, then they will be excluded from the trial.